Amyloid beta peptides and glutamatergic synaptic dysregulation

Alzheimer's disease (AD) is a major neurodegenerative disorder in which overproduction and accumulation of amyloid beta (A) peptides result in synaptic dysfunction. Recent reports strongly suggest that in the initial stages of AD glutamate receptors are dysregulated by A beta accumulation resulting in disruption of glutamatergic synaptic transmission which parallels early cognitive deficits. In the presence of A beta, 2-amino-3-(3-hydoxy-5-methylisoxazol-4-yl) propionic acid (AMPA) glutamate receptor function is disrupted and the surface expression is reduced. A beta has also been shown to modulate N-methyl-D-aspartate receptors (NMDARs) and metabotropic glutamate receptors. The A mediated glutamate receptor modifications can lead to synaptic dysfunction resulting in excitotoxic neurodegeneration during the progression of AD. This review discusses the recent findings that glutamatergic signaling could be compromised by A beta induced modulation of synaptic glutamate receptors in specific brain regions. Published by Elsevier Inc.